• Mashup Score: 0

    On October 10, 2023, the U.S. FDA granted orphan drug designation to SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of patients with AML.

    Tweet Tweets with this article
    • 🚨 NEWS 🚨 @US_FDA grants orphan drug designation to SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of patients with AML. Read more here πŸ‘‰ https://t.co/GKFLr5YPn7. #AMLsm #leusm #MedNews https://t.co/ep0WzrXkNs

  • Mashup Score: 0

    Welcome to the Transplant Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). In this session, leading experts Johannes Schetelig, MD, DKMS Group and TU Dresden, Dresden, Germany, and Gesine Bug, MD, Goethe University Frankfurt, Frankfurt, Germany, discuss whether patients with acute myeloid leukemia (AML) should receive treatment before stem cell transplantation (SCT), which was presented and debated at the 2023 SOHO Annual Meeting. The experts further discuss findings

    Tweet Tweets with this article
    • Check out our recent session with Johannes Schetelig (@tudresden_de) & Gesine Bug (@goetheuni), who discuss whether patients with AML should be treated before SCT, the ASAP trial & more: πŸ‘‰ https://t.co/3arhE4pK9A #LeuSM #BMTsm #AMLsm #HemOnc https://t.co/KA4Uv47WXF

  • Mashup Score: 0

    PURPOSE Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy for adult patients with newly diagnosed, non–favorable-risk AML. METHODS In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013), 103 participants were screened and 80 were allocated to treatment. The study was divided into four parts: dose escalation, dose expansion, investigation of alternate anthracycline and gilteritinib schedule, and continuous gilteritinib during consolidation. RESULTS After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants with FLT3-mutated AML, the composite complete response (CRc) rate was 89% (83% were conventiona

    Tweet Tweets with this article
    • Check out our key points in the image below on gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: A phase IB study in patients with newly diagnosed AML, covered here πŸ‘‡: https://t.co/JfEOu7038c #AMLsm #leusm https://t.co/yLtxZ6oqcA

  • Mashup Score: 2

    In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs

    Tweet Tweets with this article
    • Spotlight on lower-risk MDS: Revisions to the ICC and WHO classifications of MDS and AML Hear more from @sanamloghavi in our educational feature: https://t.co/MGwdJ9hRPd #MDSsm #LRMDS #AMLsm

  • Mashup Score: 0

    On September 27, 2023, it was announced that the first two patients had received SMART101 in the multicenter, open-lab, dose-escalation, phase I/II ReSET-02 trial.

    Tweet Tweets with this article
    • 🚨 NEWS 🚨 First two patients dosed in the phase I/II ReSET-02 trial to assess the safety & efficacy of SMART101, an allogeneic cell therapy, in patients with AML who have received allo-HSCT with post-transplant cyclophosphamide πŸ‘‰ https://t.co/yR7jQMYrqk #AMLsm #leusm #MedNews https://t.co/YCnXRkUqGx